Literature DB >> 23656177

Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up.

Shira Zelber-Sagi1, Roni Lotan, Oren Shibolet, Muriel Webb, Assaf Buch, Dorit Nitzan-Kaluski, Zamir Halpern, Erwin Santo, Ran Oren.   

Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is suspected to confer an increased risk for developing type 2 diabetes (DM). However, only a few prospective studies evaluated NAFLD as a predictor for DM, most did not adjust for the full range of potential cofounders and none used an objectively quantified degree of steatosis. Our aim was to evaluate the independent role of NAFLD in predicting the development of pre-DM in a 7-year prospective follow-up of healthy volunteers.
METHODS: A prospective cohort of a subsample of the Israeli National Health Survey evaluated at baseline and after 7 years by identical protocols. Metabolic parameters and ultrasonographic evidence of NAFLD were evaluated in 213 subjects, without known liver disease or history of alcohol abuse. Exclusion criteria were pre-DM at the baseline survey. Steatosis was quantified by ultrasound with the hepato-renal ultrasound index (HRI).
RESULTS: The study included 141 volunteers (mean age 48.78 ± 9.68, 24.82% with NAFLD) without pre-DM/DM at baseline. Both NAFLD on regular US (OR=2.93, 1.02-8.41 95%CI) and HRI (OR=7.87, 1.83-33.82) were independent predictors for the development of pre-DM, adjusting for age, gender, BMI, family history of DM, baseline insulin, adiponectin and glucose. Further adjustment for physical activity and dietary intake did not weaken the association. Furthermore, NAFLD was a stronger predictor for pre-DM than the metabolic syndrome. Subjects with both NAFLD and glucose ≥89 had 93.3% incidence rate of pre-DM.
CONCLUSION: Non-alcoholic fatty liver disease is a strong and independent risk factor for pre-DM in the general adult population; thus, NAFLD patients should be classified as a population at risk.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  NAFLD; hepato-renal index; prediabetes; predictors; ultrasonography

Mesh:

Year:  2013        PMID: 23656177     DOI: 10.1111/liv.12200

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  25 in total

Review 1.  Modern approach to the clinical management of non-alcoholic fatty liver disease.

Authors:  Maria Del Ben; Licia Polimeni; Francesco Baratta; Daniele Pastori; Lorenzo Loffredo; Francesco Angelico
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 2.  Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.

Authors:  Chiara Saponaro; Melania Gaggini; Amalia Gastaldelli
Journal:  Curr Diab Rep       Date:  2015-06       Impact factor: 4.810

Review 3.  Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.

Authors:  Juan P Arab; Roberto Candia; Rodrigo Zapata; Cristián Muñoz; Juan P Arancibia; Jaime Poniachik; Alejandro Soza; Francisco Fuster; Javier Brahm; Edgar Sanhueza; Jorge Contreras; M Carolina Cuellar; Marco Arrese; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 4.  Prediabetes and associated disorders.

Authors:  Martin Buysschaert; José Luís Medina; Michael Bergman; Avni Shah; Jaqueline Lonier
Journal:  Endocrine       Date:  2014-10-08       Impact factor: 3.633

5.  Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.

Authors:  Wei-Dong Li; Kun-Fa Fu; Gui-Mei Li; Yan-Shu Lian; Ai-Min Ren; Yun-Jue Chen; Jin-Rong Xia
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

6.  Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study.

Authors:  Galit Weinstein; Shira Zelber-Sagi; Sarah R Preis; Alexa S Beiser; Charles DeCarli; Elizabeth K Speliotes; Claudia L Satizabal; Ramachandran S Vasan; Sudha Seshadri
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

7.  Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes.

Authors:  Takumi Nishi; Akira Babazono; Toshiki Maeda; Takuya Imatoh; Hiroshi Une
Journal:  J Diabetes Investig       Date:  2014-11-10       Impact factor: 4.232

8.  Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study.

Authors:  Susanne Jäger; Simone Jacobs; Janine Kröger; Norbert Stefan; Andreas Fritsche; Cornelia Weikert; Heiner Boeing; Matthias B Schulze
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

9.  Association of hepatic steatosis derived from ultrasound and quantitative MRI with prediabetes in the general population.

Authors:  Till Ittermann; Henry Völzke; Muhammad Naeem; Robin Bülow; Sabine Schipf; Nicole Werner; Marcus Dörr; Markus M Lerch; Jens-Peter Kühn; Wolfgang Rathmann; Matthias Nauck; Marcello Ricardo Paulista Markus
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

10.  Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes.

Authors:  P León-Mimila; H Villamil-Ramírez; X S Li; D M Shih; S T Hui; E Ocampo-Medina; B López-Contreras; S Morán-Ramos; M Olivares-Arevalo; P Grandini-Rosales; L Macías-Kauffer; I González-González; R Hernández-Pando; F Gómez-Pérez; F Campos-Pérez; C Aguilar-Salinas; E Larrieta-Carrasco; T Villarreal-Molina; Z Wang; A J Lusis; S L Hazen; A Huertas-Vazquez; S Canizales-Quinteros
Journal:  Diabetes Metab       Date:  2020-08-10       Impact factor: 6.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.